Compare · GNPX vs NTLA
GNPX vs NTLA
Side-by-side comparison of Genprex Inc. (GNPX) and Intellia Therapeutics Inc. (NTLA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. GNPX focuses on Biotechnology: Pharmaceutical Preparations, while NTLA focuses on Biotechnology: In Vitro & In Vivo Diagnostic Substances.
- NTLA is the larger of the two at $1.34B, about 599.5x GNPX ($2.2M).
- NTLA has been more active in the news (17 items in the past 4 weeks vs 9 for GNPX).
- NTLA has more recent analyst coverage (25 ratings vs 0 for GNPX).
- Company
- Genprex Inc.
- Intellia Therapeutics Inc.
- Price
- -
- -
- Market cap
- $2.2M
- $1.34B
- 1M return
- -
- -17.96%
- 1Y return
- -
- +18.78%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- 2016
- News (4w)
- 9
- 17
- Recent ratings
- 0
- 25
Genprex Inc.
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes who currently have limited treatment options. The company works with institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Its lead product candidate is REQORSA (GPX-001), which is in preclinical stage for the treatment of non-small cell lung cancer (NSCLC). It is also developing GPX-002, a preclinical stage gene therapy for diabetes. The company also offers ONCOPREX, a nanoparticle delivery system. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
Intellia Therapeutics Inc.
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; and Ospedale San Raffaele. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Latest GNPX
- Genprex Presents Preclinical Data Identifying TROP2 as a Potential Predictive Biomarker for Reqorsa® Gene Therapy in Lung Cancer
- SEC Form 10-Q filed by Genprex Inc.
- Genprex to Highlight Dual Delivery Strategy for Diabetes Gene Therapy at Future of Cell and Gene Therapy Symposium
- Genprex Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Genprex Presents Data Showing Reqorsa® Gene Therapy Activates Cellular Repair and Maintenance Programs Linked to Aging Biology in Patients, Supporting TUSC2 as a Key Regulator of Resilience to Aging-Associated Stress
- Genprex Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Genprex Announces New Research Identifying TROP2 as a Potential Predictive Biomarker to Reqorsa® Gene Therapy in Lung Cancer
- SEC Form 8-K filed by Genprex Inc.
- Genprex to Present TUSC2 Research from Sponsored Collaboration with Meharry Medical College at the Gerontological Society of America 2026 Annual Scientific Meeting
- SEC Form 8-K filed by Genprex Inc.
Latest NTLA
- Amendment: Intellia Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Intellia Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Intellia Therapeutics Presents Additional Positive Clinical and Patient-Reported Data for Lonvoguran Ziclumeran (lonvo-z) at ACAAI 2026
- SEC Form SCHEDULE 13G filed by Intellia Therapeutics Inc.
- Intellia Therapeutics to Present at Jefferies Global Healthcare Conference in London
- Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- SEC Form 10-Q filed by Intellia Therapeutics Inc.
- Intellia Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Intellia Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates
- Intellia Therapeutics Completes Enrollment in Phase 3 MAGNITUDE-2 Trial of Nexiguran Ziclumeran (Nex-z) for Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy (ATTRv-PN)